Lynparza is the only PARP inhibitor to show patient benefit in a Phase III trial in this setting, […]

The vaccine could be Janssen’s first to win EU approval

The trial is unlikely to show a statistically significant improvement in invasive disease-free survival

The NHS Race and Health Observatory will be hosted by the NHS Confederation

Breast cancer is the most common cancer in women. But individual tumors can vary significantly, presenting different spatial […]

The ongoing COVID-19 pandemic has severely impacted the manufacturing and supply chains for many products. But while shortages […]

ASCO: Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab? chelfand Sun, 05/31/2020 – 16:58

ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data chelfand Sun, 05/31/2020 – 14:03

Pfizer’s Ibrance misses shot at big new market with early breast cancer failure chelfand Sat, 05/30/2020 – 17:46

Updated Date: Fri, 22 May 2020 00:00:00 EDT